Hospital
CCMH Corporation
CCMH Corporation was paid $11.67M by Medicaid between Jan 2018 and Dec 2024, across 131 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoCCMH CORPORATION
CARROLLTON, KY 41008
CARROLLTON, KY 41008
33aNPI1225159601assigned 04/03/2007
33bProvider typeCritical Access Hospital
28Total paid$11.67M
24GClaims224,442
24DCodes billed131
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#10 of 16
Median peer was paid$11.73M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,349 | $1.64M | |
| 2019 | 34,580 | $1.57M | |
| 2020 | 32,731 | $1.36M | |
| 2021 | 32,865 | $1.34M | |
| 2022 | 33,626 | $1.89M | |
| 2023 | 33,493 | $2.25M | |
| 2024incomplete | 23,798 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 9,701 | 8,417 | $1.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.3% | 8,866 | 7,852 | $967K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 3,665 | 3,069 | $918K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 2,414 | 1,825 | $729K |
| 80053 | Comprehensive metabolic panel | 5.7% | 16,447 | 12,747 | $664K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.6% | 1,499 | 1,275 | $538K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 760 | 684 | $472K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 880 | 779 | $422K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 14,474 | 11,409 | $393K |
| 87070 | 2.5% | 8,605 | 7,819 | $295K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 2,954 | 2,714 | $273K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 4,336 | 1,161 | $255K |
119 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 3,877 | $253K |
| 36415 | Collection of venous blood by venipuncture | 2.1% | 32,711 | $242K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 2,839 | $204K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 3,136 | $196K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,341 | $191K |
| 80061 | Lipid panel | 1.4% | 4,428 | $161K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.4% | 6,104 | $161K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 4,685 | $155K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 4,271 | $148K |
| 80305 | 1.3% | 1,710 | $147K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.2% | 550 | $142K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 3,640 | $134K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 1,148 | $133K |
| 73630 | 1.1% | 1,146 | $129K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 2,057 | $121K |
| 84484 | <1% | 3,334 | $113K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,214 | $109K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,359 | $107K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,973 | $100K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,500 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 392 | $71K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,103 | $69K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,270 | $61K |
| 83690 | <1% | 2,156 | $58K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,168 | $56K |
| 81001 | <1% | 3,820 | $54K | |
| 72100 | <1% | 545 | $52K | |
| 73610 | <1% | 534 | $47K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,310 | $46K |
| 87631 | <1% | 362 | $45K | |
| 83735 | <1% | 1,528 | $38K | |
| 87186 | <1% | 1,254 | $35K | |
| 81025 | <1% | 1,393 | $32K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 83 | $30K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,484 | $30K |
| 85027 | <1% | 1,736 | $29K | |
| 73130 | <1% | 318 | $28K | |
| 73562 | <1% | 317 | $27K | |
| 87077 | <1% | 1,602 | $27K | |
| 82150 | <1% | 840 | $25K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 433 | $25K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 714 | $24K |
| 83880 | <1% | 353 | $23K | |
| 73030 | <1% | 268 | $22K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 563 | $22K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 880 | $22K |
| 87807 | <1% | 553 | $21K | |
| 82553 | <1% | 808 | $20K | |
| 81003 | <1% | 2,323 | $20K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 213 | $20K |
| 85379 | <1% | 592 | $19K | |
| 97161 | <1% | 269 | $18K | |
| 74018 | <1% | 210 | $17K | |
| 82607 | <1% | 583 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 523 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 154 | $13K |
| 96376 | <1% | 975 | $12K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,432 | $12K |
| 83540 | <1% | 355 | $11K | |
| 86803 | <1% | 299 | $10K | |
| 87040 | <1% | 198 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,515 | $8K |
| 83605 | <1% | 404 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 992 | $8K |
| 85610 | <1% | 231 | $7K | |
| 84466 | <1% | 223 | $6K | |
| 82043 | <1% | 258 | $6K | |
| 83874 | <1% | 185 | $6K | |
| J3490 | Unclassified drugs | <1% | 467 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 26 | $5K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 54 | $5K |
| 72050 | <1% | 50 | $5K | |
| 82746 | <1% | 174 | $4K | |
| 74022 | <1% | 38 | $4K | |
| 90837 | Psychotherapy session, about an hour | <1% | 25 | $3K |
| 73110 | <1% | 32 | $3K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 88 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 246 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 349 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 28 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 50 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 115 | $2K |
| 84703 | <1% | 79 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 580 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 233 | $2K |
| 95886 | <1% | 38 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 45 | $2K |
| 86705 | <1% | 190 | $2K | |
| 82728 | <1% | 42 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 135 | $1K |
| 84439 | <1% | 45 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 326 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 102 | $974.75 |
| 82550 | <1% | 27 | $966.89 | |
| 96367 | <1% | 14 | $928.36 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29 | $903.12 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 54 | $903.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 375 | $852.88 |
| 36592 | <1% | 203 | $849.98 | |
| 80074 | <1% | 28 | $837.73 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 46 | $746.44 |
| 90715 | <1% | 34 | $636.84 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 159 | $624.79 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 102 | $563.04 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 135 | $529.19 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 22 | $491.90 |
| 84480 | <1% | 13 | $375.51 | |
| 80320 | <1% | 12 | $346.36 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 82 | $273.87 |
| 85730 | <1% | 16 | $193.71 | |
| 01992 | <1% | 34 | $190.40 | |
| 0012A | <1% | 13 | $167.73 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 44 | $134.40 |
| 12001 | <1% | 15 | $116.88 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16 | $86.00 |
| 90686 | <1% | 14 | $71.28 | |
| J1435 | Injection, estrone, per 1 mg | <1% | 24 | $52.92 |
| 91301 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOMLINSON, SHEILA (DIRECTOR OF CLINICAL SERVICES)
| Provider | Location | Paid |
|---|---|---|
| CCMH Corporation | Carrollton, KY | $1.58M |
| CCMH Corporation | Carrollton, KY | $409K |
| CCMH Corporation | Warsaw, KY | $341K |
| CCMH Corporation | Carrollton, KY | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.